Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 841,202
  • Shares Outstanding, K 44,960
  • Annual Sales, $ 71,620 K
  • Annual Income, $ -43,100 K
  • 36-Month Beta 0.81
  • Price/Sales 11.85
  • Price/Cash Flow N/A
  • Price/Book 17.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.42
  • Number of Estimates 7
  • High Estimate 0.00
  • Low Estimate -0.67
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.84 +5.55%
on 09/17/18
24.34 -22.64%
on 08/29/18
-3.73 (-16.53%)
since 08/20/18
3-Month
17.84 +5.55%
on 09/17/18
27.20 -30.77%
on 07/25/18
-6.85 (-26.67%)
since 06/20/18
52-Week
17.02 +10.63%
on 09/26/17
35.00 -46.20%
on 03/08/18
+1.18 (+6.69%)
since 09/20/17

Most Recent Stories

More News
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 18.79 (+0.43%)
CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody(TM) therapeutic...

CTMX : 18.79 (+0.43%)
Report: Developing Opportunities within OMNOVA Solutions, Natural Health Trends, Vocera Communications, Oppenheimer, CytomX Therapeutics, and The Ultimate Software Group -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OMNOVA Solutions Inc. (NYSE:OMN),...

OMN : 10.20 (+2.51%)
CTMX : 18.79 (+0.43%)
VCRA : 34.87 (-0.46%)
OPY : 31.95 (+1.59%)
ULTI : 315.44 (+0.81%)
NHTC : 23.65 (+0.30%)
CytomX Therapeutics to Announce Second Quarter 2018 Financial Results

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 18.79 (+0.43%)
Pandion Therapeutics Announces Appointment of Nancy Stagliano to Its Board of Directors

Pandion Therapeutics, Inc., a biotechnology company developing novel therapeutics to treat autoimmune and inflammatory diseases and transplant rejection, today announced that Nancy...

CTMX : 18.79 (+0.43%)
BMY : 61.55 (+1.23%)
Dow Spends Fifth Day in the Green

Dow Spends Fifth Day in the Green

WERN : 36.85 (+0.14%)
CTMX : 18.79 (+0.43%)
BBY : 79.39 (+2.12%)
VNDA : 19.75 (+0.51%)
CytomX Therapeutics Announces Closing of Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 18.79 (+0.43%)
Look for Shares of Cytomx Therapeut to Potentially Rebound after Yesterday's 9.79% Sell Off

Cytomx Therapeut (NASDAQ:CTMX) traded in a range yesterday that spanned from a low of $22.83 to a high of $25.20. Yesterday, the shares fell 9.8%, which took the trading range below the 3-day low of...

CTMX : 18.79 (+0.43%)
CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 18.79 (+0.43%)
CytomX Therapeutics Announces Proposed Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 18.79 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 19.58
1st Resistance Point 19.15
Last Price 18.79
1st Support Level 18.24
2nd Support Level 17.76

See More

52-Week High 35.00
Fibonacci 61.8% 28.13
Fibonacci 50% 26.01
Fibonacci 38.2% 23.89
Last Price 18.79
52-Week Low 17.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar